Each year, Septic Shock affects more than 30 million people worldwide and is one of the leading causes of death among critically ill patients globally.

The market for systemic inflammatory response syndrome treatment is led by the United States, followed by Europe and the Asia-Pacific region.

Given that the inflammatory process of Septic Shock is present in multiple conditions (AIS, MI, etc.), the market potential is significant. According to a report by Precedence Research, the Septic Shock treatment market is expected to grow from USD 10.49 billion to USD 21.36 billion between 2020 and 2030 (CAGR of 8%). The intensive care market, including Septic Shock, acute ischemic stroke, and acute myocardial infarction, is estimated at USD 54 billion.

The global market revenue for organ transplant rejection drugs is expected to reach USD 7.4 billion by 2032, with a CAGR of 3.4% between 2023 and 2032.

The key drivers of the organ transplant rejection drug market include the increasing demand from patients, technological advancements, and evolving consumer preferences towards health and well-being.

In 2022, North America dominated with 43% of the market share for transplant rejection drugs. The Asia-Pacific market is expected to grow, with an estimated CAGR of about 3.9% from 2023 to 2032.

The major players include Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, and F. Hoffmann-La Roche Ltd.